

## United States Patent and Trademark Office

UNITED STATES, DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,755	05/14/2001	David Elliott Spaner	033136-176	8477
7:	590 08/19/2003			
Gerald F. Swiss, Esq. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, VA 22313-1404			EXAMINER	
			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	10
			DATE MAILED: 08/19/2003	10

Please find below and/or attached an Office communication concerning this application or proceeding.



## Office Action Summary

Application No. App

09/853,755

Applicant(s)

Spaner

Examiner

G.R. Ewoldt, Ph.D.

Art Unit 1644

	The MAILING DATE of this communication appears of	on the cover sheet with the correspondence address				
Period f	for Reply					
THE N	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be available under the provision of 27 CER 1.136 (s). In an avert because the street filed of the SIX (S) MONTHS (s) at the					
mailing	- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.					
<ul> <li>If NO p</li> <li>Failure</li> <li>Any rep</li> </ul>	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply an to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).				
Status						
1) 💢	Responsive to communication(s) filed on Jun 9, 200	23				
2a) 🗌	This action is <b>FINAL</b> . 2b)   ✓ This action	on is non-final.				
	Since this application is in condition for allowance exclosed in accordance with the practice under Ex part	except for formal matters, prosecution as to the merits is rete Quayle, 1935 C.D. 11; 453 O.G. 213.				
	tion of Claims					
4) 💢	Claim(s) 21 and 22	is/are pending in the application.				
	•	is/are withdrawn from consideration.				
5) 🗌	Claim(s)	is/are allowed.				
	Claim(s) 21 and 22					
	Claim(s)					
		are subject to restriction and/or election requirement.				
Application Papers						
9) 🗆	The specification is objected to by the Examiner.					
10)□	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.				
	Applicant may not request that any objection to the dra					
11)		is: a) $\square$ approved b) $\square$ disapproved by the Examiner.				
	If approved, corrected drawings are required in reply to					
12)	The oath or declaration is objected to by the Examin	ner.				
Priority (	under 35 U.S.C. §§ 119 and 120					
13)🗶	Acknowledgement is made of a claim for foreign prid	ority under 35 U.S.C. § 119(a)-(d) or (f).				
a) 🗶	a) ☑ All b) ☐ Some* c) ☐ None of:					
1	1. Certified copies of the priority documents have been received.					
2	2. X Certified copies of the priority documents have	been received in Application No. 09/363,678 .				
	application from the International Bureau	ocuments have been received in this National Stage to (PCT Rule 17.2(a)).				
	the attached detailed Office action for a list of the					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) The translation of the foreign language provisional application has been received.						
	Acknowledgement is made of a claim for domestic partiel	priority under 35 U.S.C. §§ 120 and/or 121.				
Attachme 1) 🔲 Noti		4) Interview Summary (PTO-413) Paper No(s).				
		5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 3-7 6) Other:						

Serial No. 09/853,755 Art Unit 1644

## DETAILED ACTION

- 1. Applicant's election without traverse of Group II, Claims 21 and 22, in Paper No. 9, filed 6/09/03, is acknowledged.
- Claims 1-14 have been canceled.
   Claims 21 and 22 are pending and being acted upon.
- 3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in-
- (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of
- this subsection based on the filing of an international application filed under the treaty defined in section 351(a).
- 4. Claims 21 and 22 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by U.S. Patent No. 5,980,954 (IDS).

The '954 patent teaches a population of mammalian T cells (peripheral blood mononuclear cells) essentially free of stem cells, having been subjected *in vitro* to oxidative stress (see particularly column 4, line 65 - column 5, line 4).

The reference clearly anticipates the claimed invention.

5. Claims 21 and 22 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by W0 98/07436 (IDS).

W0 98/07436 teaches a population of mammalian T cells (peripheral blood mononuclear cells) essentially free of stem cells, having been subjected *in vitro* to oxidative stress (see particularly page 8, second paragraph).

The reference clearly anticipates the claimed invention.

- 6. No claim is allowed.
- 7. EPO 0339927A on the IDS filed 11/12/02, was not submitted, instead, Applicant submitted EPO 0339924A. Neither was the Sheng-Tanner et al. abstract submitted. Instead, Applicant submitted an abstract of Spaner et al., "Prevention of Major MHC Disparate GVHD by the Use of Multiple Physicochemical Stressors" of unknown origin.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:00 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

G.R. Ewoldt, Ph.D.

G.R. Ewoldt, Ph.D.
Primary Examiner
Technology Center 1600

August 19, 2003